{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:52:47Z","timestamp":1791899567914,"version":"4.3.4"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015615","name":"National Drug Abuse Treatment Clinical Trials Network","doi-asserted-by":"publisher","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}],"id":[{"id":"10.13039\/100015615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01DA055130"],"award-info":[{"award-number":["K01DA055130"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA044829\/UH3DA044829"],"award-info":[{"award-number":["UG3DA044829\/UH3DA044829"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA044798\/UH3DA044798"],"award-info":[{"award-number":["UG3DA044798\/UH3DA044798"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA044830\/UH3DA044830"],"award-info":[{"award-number":["UG3DA044830\/UH3DA044830"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA044823\/UH3DA044823"],"award-info":[{"award-number":["UG3DA044823\/UH3DA044823"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3DA044822\/UH3DA044822"],"award-info":[{"award-number":["UH3DA044822\/UH3DA044822"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA044831\/UH3DA044831"],"award-info":[{"award-number":["UG3DA044831\/UH3DA044831"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA044825"],"award-info":[{"award-number":["UG3DA044825"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA044826\/UH3DA044826"],"award-info":[{"award-number":["UG3DA044826\/UH3DA044826"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U24DA044801"],"award-info":[{"award-number":["U24DA044801"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UL1TR002369"],"award-info":[{"award-number":["UL1TR002369"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K12HS026370"],"award-info":[{"award-number":["K12HS026370"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Co-use of stimulants and opioids is rapidly increasing. Randomized clinical trials (RCTs) have established the efficacy of medications for opioid use disorder (MOUD), but stimulant use may decrease the likelihood of initiating MOUD treatment. Furthermore, trial participants may not represent \u201creal-world\u201d populations who would benefit from treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a two-stage analysis. First, associations between stimulant use (time-varying urine drug screens for cocaine, methamphetamine, or amphetamines) and initiation of buprenorphine or extended-release naltrexone (XR-NTX) were estimated across two RCTs (CTN-0051 X:BOT and CTN-0067 CHOICES) using adjusted Cox regression models. Second, results were generalized to three target populations who would benefit from MOUD: Housed adults identifying the need for OUD treatment, as characterized by the National Survey on Drug Use and Health (NSDUH); adults entering OUD treatment, as characterized by Treatment Episodes Dataset (TEDS); and adults living in rural regions of the U.S. with high rates of injection drug use, as characterized by the Rural Opioids Initiative (ROI). Generalizability analyses adjusted for differences in demographic characteristics, substance use, housing status, and depression between RCT and target populations using inverse probability of selection weighting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Analyses included 673 clinical trial participants, 139 NSDUH respondents (weighted to represent 661,650 people), 71,751 TEDS treatment episodes, and 1,933 ROI participants. The majority were aged 30\u201349 years, male, and non-Hispanic White. In RCTs, stimulant use reduced the likelihood of MOUD initiation by 32% (adjusted HR [aHR]\u2009=\u20090.68, 95% CI 0.49\u20130.94, <jats:italic>p<\/jats:italic>\u2009=\u20090.019). Stimulant use associations were slightly attenuated and non-significant among housed adults needing treatment (25% reduction, aHR\u2009=\u20090.75, 0.48\u20131.18, <jats:italic>p<\/jats:italic>\u2009=\u20090.215) and adults entering OUD treatment (28% reduction, aHR\u2009=\u20090.72, 0.51\u20131.01, <jats:italic>p<\/jats:italic>\u2009=\u20090.061). The association was more pronounced, but still non-significant among rural people injecting drugs (39% reduction, aHR\u2009=\u20090.61, 0.35\u20131.06, <jats:italic>p<\/jats:italic>\u2009=\u20090.081). Stimulant use had a larger negative impact on XR-NTX initiation compared to buprenorphine, especially in the rural population (76% reduction, aHR\u2009=\u20090.24, 0.08\u20130.69, <jats:italic>p<\/jats:italic>\u2009=\u20090.008).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Stimulant use is a barrier to buprenorphine or XR-NTX initiation in clinical trials and real-world populations that would benefit from OUD treatment. Interventions to address stimulant use among patients with OUD are urgently needed, especially among rural people injecting drugs, who already suffer from limited access to MOUD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-023-00364-3","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T16:18:55Z","timestamp":1676909935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8754-995X","authenticated-orcid":false,"given":"R. R.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Foot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. A.","family":"Arah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E.","family":"Rudolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. X.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. I.","family":"Tsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. A.","family":"Levander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. T.","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"364_CR1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320.","journal-title":"Drug Alcohol Depend"},{"key":"364_CR2","doi-asserted-by":"publisher","first-page":"107592","DOI":"10.1016\/j.drugalcdep.2019.107592","volume":"204","author":"JC Strickland","year":"2019","unstructured":"Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of \u201ctwin epidemics\u201d: rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204:107592.","journal-title":"Drug Alcohol Depend"},{"key":"364_CR3","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.addbeh.2020.106680","volume":"113","author":"RD Goodwin","year":"2021","unstructured":"Goodwin RD, Moeller SJ, Zhu J, Yarden J, Ganzhorn S, Williams JM. The potential role of cocaine and heroin co-use in the opioid epidemic in the United States. Addict Behav. 2021;113:106680.","journal-title":"Addict Behav"},{"key":"364_CR4","unstructured":"Ahmad FB, Rossen LM, Sutton P. Provisional drug overdose death counts, for 12 months ending November 2021, updated April, 2022. National Center for Health Statistics;\u00a02022.\u00a0https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"issue":"34","key":"364_CR5","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15585\/mmwr.mm6834a2","volume":"68","author":"RM Gladden","year":"2019","unstructured":"Gladden RM, O\u2019Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid type and presence of benzodiazepines, cocaine, and methamphetamine\u201425 states, July\u2013December 2017 to January\u2013June 2018. MMWR Morb Mortal Wkly Rep. 2019;68(34):737\u201344.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"364_CR6","doi-asserted-by":"publisher","first-page":"108314","DOI":"10.1016\/j.drugalcdep.2020.108314","volume":"216","author":"CL Shover","year":"2020","unstructured":"Shover CL, Falasinnu TO, Dwyer CL, Santos NB, Cunningham NJ, Freedman RB, et al. Steep increases in fentanyl-related mortality west of the Mississippi river: recent evidence from county and state surveillance. Drug Alcohol Depend. 2020;216:108314.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"364_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2006.07.009","volume":"87","author":"T Kerr","year":"2007","unstructured":"Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007;87(1):39\u201345.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"364_CR8","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.","journal-title":"JAMA Netw Open"},{"key":"364_CR9","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.","journal-title":"BMJ"},{"issue":"10118","key":"364_CR10","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","volume":"391","author":"JD Lee","year":"2018","unstructured":"Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine\u2013naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309\u201318.","journal-title":"Lancet"},{"issue":"5","key":"364_CR11","doi-asserted-by":"publisher","first-page":"e2211363","DOI":"10.1001\/jamanetworkopen.2022.11363","volume":"5","author":"KY Xu","year":"2022","unstructured":"Xu KY, Mintz CM, Presnall N, Bierut LJ, Grucza RA. Comparative effectiveness associated with buprenorphine and naltrexone in opioid use disorder and cooccurring polysubstance use. JAMA Netw Open. 2022;5(5):e2211363.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"364_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/ADM.0000000000000726","volume":"15","author":"BR Ford","year":"2021","unstructured":"Ford BR, Bart G, Grahan B, Shearer RD, Winkelman TNA. Associations between polysubstance use patterns and receipt of medications for opioid use disorder among adults in treatment for opioid use disorder. J Addict Med. 2021;15(2):159\u201362.","journal-title":"J Addict Med"},{"issue":"1","key":"364_CR13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13722-021-00266-2","volume":"16","author":"MC Frost","year":"2021","unstructured":"Frost MC, Lampert H, Tsui JI, Iles-Shih MD, Williams EC. The impact of methamphetamine\/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review. Addict Sci Clin Pract. 2021;16(1):62.","journal-title":"Addict Sci Clin Pract"},{"issue":"4","key":"364_CR14","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1521-0391.2013.12032.x","volume":"22","author":"CO Cunningham","year":"2013","unstructured":"Cunningham CO, Giovanniello A, Kunins HV, Roose RJ, Fox AD, Sohler NL. Buprenorphine treatment outcomes among opioid-dependent cocaine users and non-users. Am J Addict. 2013;22(4):352\u20137.","journal-title":"Am J Addict"},{"key":"364_CR15","doi-asserted-by":"publisher","first-page":"108830","DOI":"10.1016\/j.jsat.2022.108830","volume":"143","author":"AM Bunting","year":"2022","unstructured":"Bunting AM, Krawczyk N, Choo TH, Pavlicova M, McNeely J, Tofighi B, et al. Polysubstance use before and during treatment with medication for opioid use disorder: prevalence and association with treatment outcomes. J Subst Abuse Treat. 2022;143:108830.","journal-title":"J Subst Abuse Treat"},{"key":"364_CR16","doi-asserted-by":"publisher","first-page":"108537","DOI":"10.1016\/j.drugalcdep.2021.108537","volume":"221","author":"CL Rowe","year":"2021","unstructured":"Rowe CL, Santos GM, Kornbluh W, Bhardwaj S, Faul M, Coffin PO. Using ICD-10-CM codes to detect illicit substance use: a comparison with retrospective self-report. Drug Alcohol Depend. 2021;221:108537.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"364_CR17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/add.14812","volume":"115","author":"CM Jones","year":"2020","unstructured":"Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008\u201317. Addiction. 2020;115(2):347\u201353.","journal-title":"Addiction"},{"key":"364_CR18","doi-asserted-by":"publisher","first-page":"108193","DOI":"10.1016\/j.drugalcdep.2020.108193","volume":"216","author":"B Chan","year":"2020","unstructured":"Chan B, Freeman M, Ayers C, Korthuis PT, Paynter R, Kondo K, et al. A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders. Drug Alcohol Depend. 2020;216:108193.","journal-title":"Drug Alcohol Depend"},{"key":"364_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","volume":"16","author":"T Kennedy-Martin","year":"2015","unstructured":"Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495.","journal-title":"Trials"},{"issue":"7","key":"364_CR20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/add.13327","volume":"111","author":"R Susukida","year":"2016","unstructured":"Susukida R, Crum RM, Stuart EA, Ebnesajjad C, Mojtabai R. Assessing sample representativeness in randomized controlled trials: application to the National Institute of drug abuse clinical trials network. Addiction. 2016;111(7):1226\u201334.","journal-title":"Addiction"},{"issue":"4","key":"364_CR21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1176\/appi.ajp.157.4.588","volume":"157","author":"K Humphreys","year":"2000","unstructured":"Humphreys K, Weisner C. Use of exclusion criteria in selecting research subjects and its effect on the generalizability of alcohol treatment outcome studies. Am J Psychiatry. 2000;157(4):588\u201394.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"364_CR22","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1111\/j.1530-0277.2007.00391.x","volume":"31","author":"K Humphreys","year":"2007","unstructured":"Humphreys K, Weingardt KR, Harris AH. Influence of subject eligibility criteria on compliance with national institutes of health guidelines for inclusion of women, minorities, and children in treatment research. Alcohol Clin Exp Res. 2007;31(6):988\u201395.","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"364_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/10826084.2016.1240695","volume":"52","author":"J Storbjork","year":"2017","unstructured":"Storbjork J, Garfield JB, Larner A. Implications of eligibility criteria on the generalizability of alcohol and drug treatment outcome research: a study of real-world treatment seekers in Sweden and in Australia. Subst Use Misuse. 2017;52(4):439\u201350.","journal-title":"Subst Use Misuse"},{"issue":"4","key":"364_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/08897077.2018.1526843","volume":"39","author":"SS Kelpin","year":"2018","unstructured":"Kelpin SS, Ondersma SJ, Weaver M, Svikis DS. Representativeness of patients enrolled in a primary care clinical trial for heavy\/problem substance use. Subst Abus. 2018;39(4):469\u201375.","journal-title":"Subst Abus"},{"issue":"1\u20132","key":"364_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.drugalcdep.2008.05.002","volume":"98","author":"C Blanco","year":"2008","unstructured":"Blanco C, Olfson M, Okuda M, Nunes EV, Liu SM, Hasin DS. Generalizability of clinical trials for alcohol dependence to community samples. Drug Alcohol Depend. 2008;98(1\u20132):123\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20132","key":"364_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.drugalcdep.2010.04.009","volume":"111","author":"M Okuda","year":"2010","unstructured":"Okuda M, Hasin DS, Olfson M, Khan SS, Nunes EV, Montoya I, et al. Generalizability of clinical trials for cannabis dependence to community samples. Drug Alcohol Depend. 2010;111(1\u20132):177\u201381.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"364_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/00952990.2019.1694536","volume":"46","author":"JJ Lister","year":"2020","unstructured":"Lister JJ, Weaver A, Ellis JD, Himle JA, Ledgerwood DM. A systematic review of rural-specific barriers to medication treatment for opioid use disorder in the United States. Am J Drug Alcohol Abuse. 2020;46(3):273\u201388.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"364_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.4155\/cli.14.21","volume":"4","author":"E Seidler","year":"2014","unstructured":"Seidler E, Keshaviah A, Brown CL, Wood E, Granick L, Kimball A. Geographic distribution of clinical trials may lead to inequities in access. Clin Invest. 2014;4:373\u201380.","journal-title":"Clin Invest"},{"issue":"5","key":"364_CR29","doi-asserted-by":"publisher","first-page":"e2625","DOI":"10.1002\/hup.2625","volume":"32","author":"SE McCabe","year":"2017","unstructured":"McCabe SE, West BT, Jutkiewicz EM, Boyd CJ. Multiple DSM-5 substance use disorders: a national study of US adults. Hum Psychopharmacol. 2017;32(5):e2625.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"364_CR30","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.3346\/jkms.2019.34.e28","volume":"34","author":"HS Kim","year":"2019","unstructured":"Kim HS, Kim JH. Proceed with caution when using real world data and real world evidence. J Korean Med Sci. 2019;34(4):e28.","journal-title":"J Korean Med Sci"},{"issue":"27","key":"364_CR31","doi-asserted-by":"publisher","first-page":"7345","DOI":"10.1073\/pnas.1510507113","volume":"113","author":"E Bareinboim","year":"2016","unstructured":"Bareinboim E, Pearl J. Causal inference and the data-fusion problem. Proc Natl Acad Sci. 2016;113(27):7345\u201352.","journal-title":"Proc Natl Acad Sci"},{"key":"364_CR32","doi-asserted-by":"publisher","DOI":"10.21236\/ADA557437","volume-title":"Transportability across studies: a formal approach","author":"J Pearl","year":"2011","unstructured":"Pearl J, Bareinboim E. Transportability across studies: a formal approach. California: University of Los Angeles; 2011."},{"issue":"4","key":"364_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1214\/14-STS486","volume":"29","author":"J Pearl","year":"2014","unstructured":"Pearl J, Bareinboim E. External validity: from Do-Calculus to transportability across populations. Stat Sci. 2014;29(4):579\u201395.","journal-title":"Stat Sci"},{"issue":"7","key":"364_CR34","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/add.15836","volume":"117","author":"PT Korthuis","year":"2022","unstructured":"Korthuis PT, Cook RR, Lum PJ, Waddell EN, Tookes H, Vergara-Rodriguez P, et al. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. Addiction. 2022;117(7):1961\u201371.","journal-title":"Addiction"},{"key":"364_CR35","unstructured":"National Center for Health Statistics. Data hosting: national survey on drug use and health. https:\/\/www.cdc.gov\/rdc\/b1datatype\/nsduh.htm."},{"key":"364_CR36","unstructured":"The Substance Use and Mental Health Services Administration. Treatment episode dataset: admissions.\u00a0https:\/\/www.datafiles.samhsa.gov\/study-series\/treatment-episode-data-set-admissions-teds-nid13518."},{"issue":"1","key":"364_CR37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13722-022-00322-5","volume":"17","author":"RA Jenkins","year":"2022","unstructured":"Jenkins RA, Whitney BM, Nance RM, Allen TM, Cooper HLF, Feinberg J, et al. The rural opioid initiative consortium description: providing evidence to understand the fourth wave of the opioid crisis. Addict Sci Clin Pract. 2022;17(1):38.","journal-title":"Addict Sci Clin Pract"},{"issue":"6","key":"364_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/17843286.2000.11754319","volume":"55","author":"M Vandevenne","year":"2000","unstructured":"Vandevenne M, Vandenbussche H, Verstraete A. Detection time of drugs of abuse in urine. Acta Clin Belg. 2000;55(6):323\u201333.","journal-title":"Acta Clin Belg"},{"issue":"1","key":"364_CR39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329","volume":"20","author":"MJ Azur","year":"2011","unstructured":"Azur MJ, Stuart EA, Frangakis C, Leaf PJ. Multiple imputation by chained equations: what is it and how does it work? Int J Methods Psychiatr Res. 2011;20(1):40\u20139.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"34","key":"364_CR40","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.15585\/mmwr.mm7034a2","volume":"70","author":"S Liu","year":"2021","unstructured":"Liu S, O\u2019Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines\u201438 states and the District of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136\u201341.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"364_CR41","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/rssb.12299","volume":"81","author":"A Luedtke","year":"2019","unstructured":"Luedtke A, Carone M, van der Laan MJ. An omnibus non-parametric test of equality in distribution for unknown functions. J R Stat Soc Ser B (Stat Methodol). 2019;81(1):75\u201399.","journal-title":"J R Stat Soc Ser B (Stat Methodol)"},{"issue":"1","key":"364_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/aje\/kwq084","volume":"172","author":"SR Cole","year":"2010","unstructured":"Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to target populations: the ACTG 320 trial. Am J Epidemiol. 2010;172(1):107\u201315.","journal-title":"Am J Epidemiol"},{"issue":"5","key":"364_CR43","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/sim.8822","volume":"40","author":"B Ackerman","year":"2020","unstructured":"Ackerman B, Lesko CR, Siddique J, Susukida R, Stuart EA. Generalizing randomized trial findings to a target population using complex survey population data. Stat Med. 2020;40(5):1101\u201320.","journal-title":"Stat Med"},{"issue":"6","key":"364_CR44","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1093\/aje\/kwn164","volume":"168","author":"SR Cole","year":"2008","unstructured":"Cole SR, Hern\u00e1n MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168(6):656\u201364.","journal-title":"Am J Epidemiol"},{"issue":"28","key":"364_CR45","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661\u201379.","journal-title":"Stat Med"},{"key":"364_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/ADM.0000000000000611","volume":"14","author":"H Englander","year":"2019","unstructured":"Englander H, King C, Nicolaidis C, Collins D, Patten A, Gregg J, et al. Predictors of opioid and alcohol pharmacotherapy initiation at hospital discharge among patients seen by an inpatient addiction consult service. J Addict Med. 2019;14:415.","journal-title":"J Addict Med"},{"issue":"1","key":"364_CR47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/add.15116","volume":"116","author":"LA Lin","year":"2021","unstructured":"Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM, et al. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction. 2021;116(1):96\u2013104.","journal-title":"Addiction"},{"key":"364_CR48","unstructured":"Center for Substance Abuse T. SAMHSA\/CSAT treatment improvement protocols.\u00a0 Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Rockville: Substance Abuse and Mental Health Services Administration; 2004."},{"issue":"2","key":"364_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/ADM.0000000000000635","volume":"14","author":"K Crotty","year":"2020","unstructured":"Crotty K, Freedman KI, Kampman KM. Executive summary of the focused update of the ASAM national practice guideline for the treatment of opioid use disorder. J Addict Med. 2020;14(2):99\u2013112.","journal-title":"J Addict Med"},{"key":"364_CR50","doi-asserted-by":"publisher","first-page":"103098","DOI":"10.1016\/j.drugpo.2020.103098","volume":"91","author":"AM Lopez","year":"2021","unstructured":"Lopez AM, Dhatt Z, Howe M, Al-Nassir M, Billing A, Artigiani E, et al. Co-use of methamphetamine and opioids among people in treatment in Oregon: a qualitative examination of interrelated structural, community, and individual-level factors. Int J Drug Policy. 2021;91:103098.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"364_CR51","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1186\/s12889-021-12104-w","volume":"21","author":"C Russell","year":"2021","unstructured":"Russell C, Ali F, Nafeh F, LeBlanc S, Imtiaz S, Elton-Marshall T, et al. A qualitative examination of substance use service needs among people who use drugs (PWUD) with treatment and service experience in Ontario, Canada. BMC Public Health. 2021;21(1):2021.","journal-title":"BMC Public Health"},{"issue":"9","key":"364_CR52","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1001\/jamapsychiatry.2020.0246","volume":"77","author":"MP Paulus","year":"2020","unstructured":"Paulus MP, Stewart JL, Neurobiology. Clinical presentation, and treatment of methamphetamine use disorder: a review. JAMA Psychiatry. 2020;77(9):959\u201366.","journal-title":"JAMA Psychiatry"},{"key":"364_CR53","doi-asserted-by":"publisher","first-page":"108183","DOI":"10.1016\/j.jsat.2020.108183","volume":"122","author":"P Gauthier","year":"2021","unstructured":"Gauthier P, Greco P, Meyers-Ohki S, Desai A, Rotrosen J. Patients\u2019 perspectives on initiating treatment with extended-release naltrexone (XR-NTX). J Subst Abus Treat. 2021;122:108183.","journal-title":"J Subst Abus Treat"},{"issue":"8","key":"364_CR54","doi-asserted-by":"publisher","first-page":"e2226544","DOI":"10.1001\/jamanetworkopen.2022.26544","volume":"5","author":"PT Korthuis","year":"2022","unstructured":"Korthuis PT, Cook RR, Foot CA, Leichtling G, Tsui JI, Stopka TJ, et al. Association of methamphetamine and opioid use with nonfatal overdose in rural communities. JAMA Netw Open. 2022;5(8):e2226544.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"364_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.15585\/mmwr.mm6912a1","volume":"69","author":"CM Jones","year":"2020","unstructured":"Jones CM, Compton WM, Mustaquim D. Patterns and characteristics of methamphetamine use among adults\u2014United States, 2015\u20132018. MMWR Morb Mortal Wkly Rep. 2020;69(12):317\u201323.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"364_CR56","doi-asserted-by":"publisher","first-page":"109077","DOI":"10.1016\/j.drugalcdep.2021.109077","volume":"228","author":"RR Cook","year":"2021","unstructured":"Cook RR, Torralva R, King C, Lum PJ, Tookes H, Foot C, et al. Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease. Drug Alcohol Depend. 2021;228:109077.","journal-title":"Drug Alcohol Depend"},{"key":"364_CR57","doi-asserted-by":"publisher","first-page":"108307","DOI":"10.1016\/j.drugalcdep.2020.108307","volume":"216","author":"HD Brown","year":"2020","unstructured":"Brown HD, DeFulio A. Contingency management for the treatment of methamphetamine use disorder: a systematic review. Drug Alcohol Depend. 2020;216:108307.","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"364_CR58","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","volume":"77","author":"PO Coffin","year":"2020","unstructured":"Coffin PO, Santos GM, Hern J, Vittinghoff E, Walker JE, Matheson T, et al. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatry. 2020;77(3):246\u201355.","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"364_CR59","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","volume":"384","author":"MH Trivedi","year":"2021","unstructured":"Trivedi MH, Walker R, Ling W, Dela Cruz A, Sharma G, Carmody T, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140\u201353.","journal-title":"N Engl J Med"},{"issue":"1","key":"364_CR60","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/ADM.0000000000000810","volume":"16","author":"E Stack","year":"2022","unstructured":"Stack E, Hildebran C, Leichtling G, Waddell EN, Leahy JM, Martin E, et al. Peer recovery support services across the continuum: in community, hospital, corrections, and treatment and recovery agency settings\u2014a narrative review. J Addict Med. 2022;16(1):93\u2013100.","journal-title":"J Addict Med"},{"issue":"12","key":"364_CR61","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1158\/1055-9965.EPI-21-0585","volume":"30","author":"K Inoue","year":"2021","unstructured":"Inoue K, Hsu W, Arah OA, Prosper AE, Aberle DR, Bui AAT. Generalizability and transportability of the national lung screening trial data: extending trial results to different populations. Cancer Epidemiol Biomark Prev. 2021;30(12):2227\u201334.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"364_CR62","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/08897077.2019.1640831","volume":"41","author":"A Manhapra","year":"2020","unstructured":"Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what? Subst Abus. 2020;41(1):110\u201320.","journal-title":"Subst Abus"},{"key":"364_CR63","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","volume":"85","author":"JR Morgan","year":"2018","unstructured":"Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abus Treat. 2018;85:90\u20136.","journal-title":"J Subst Abus Treat"},{"issue":"6","key":"364_CR64","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1001\/jama.2019.20844","volume":"323","author":"B Han","year":"2020","unstructured":"Han B, Volkow ND, Compton WM, McCance-Katz EF. Reported heroin use, use disorder, and injection among adults in the United States, 2002\u20132018. JAMA. 2020;323(6):568\u201371.","journal-title":"JAMA"},{"key":"364_CR65","first-page":"1","volume-title":"Comparing and evaluating substance use treatment utilization estimates from the national survey on drug use and health and other data sources. CBHSQ data review","author":"K Batts","year":"2012","unstructured":"Batts K, Pemberton M, Bose J, Weimer B, Henderson L, Penne M, et al. Comparing and evaluating substance use treatment utilization estimates from the national survey on drug use and health and other data sources. CBHSQ data review. Rockville: Substance Abuse and Mental Health Services Administration; 2012. p. 1\u2013120."},{"issue":"9","key":"364_CR66","doi-asserted-by":"publisher","first-page":"e2123019","DOI":"10.1001\/jamanetworkopen.2021.23019","volume":"4","author":"B Saloner","year":"2021","unstructured":"Saloner B, Whitley P, LaRue L, Dawson E, Huskey A. Polysubstance use among patients treated with buprenorphine from a national urine drug test database. JAMA Netw Open. 2021;4(9):e2123019.","journal-title":"JAMA Netw Open"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00364-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-023-00364-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-023-00364-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T16:19:06Z","timestamp":1676909946000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-023-00364-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["364"],"URL":"https:\/\/doi.org\/10.1186\/s13722-023-00364-3","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"29 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All included studies were conducted with ethical approval and all included participants provided informed consent prior to participation. CHOICES was approved by the Advarra Institutional Review Board (IRB00000971), with participating sites deferring to its regulatory role, while each site in X:BOT and the ROI received local IRB approval prior to trial initiation. The NSDUH and TEDS are collected by the U.S. Substance Abuse and Mental Health Services Administration under federal privacy and confidentiality laws and regulations ().","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}